Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo

PURPOSE: To provide rationale for using PI3K and/or MAPK pathway inhibitors to treat rhabdomyosarcomas (RMS), a major cause of pediatric/adolescent cancer deaths. EXPERIMENTAL DESIGN: The prevalence of PI3K/MAPK pathway activation in RMS clinical samples was assessed using immunohistochemistry. Comp...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Renshaw, Jane, Taylor, Kathryn R., Bishop, Ryan, Valenti, Melanie, De Haven Brandon, Alexis, Gowan, Sharon, Eccles, Suzanne A., Ruddle, Ruth R., Johnson, Louise D., Raynaud, Florence I., Selfe, Joanna L., Thway, Khin, Pietsch, Torsten, Pearson, Andrew D., Shipley, Janet
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2013
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3818134/
https://ncbi.nlm.nih.gov/pubmed/23918606
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-0850
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia